[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623319":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":13,"centralContacts":17,"locations":26,"responsibleParty":44,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":74,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"Pulse-Field Ablation",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Radiofrequency Catheter Ablation",[14],{"name":15,"affiliation":5,"role":16},"Carine Paré","STUDY_DIRECTOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Mikael Laredo, MD, PhD","CONTACT","+33 1 42 16 30 81","mikael.laredo@aphp.fr",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":10},"Nadjia Kachenoura, PhD","+33 1 44 27 91 16",[27],{"facility":28,"status":10,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Hôpital Pitié Salpêtrière","Paris","Île-de-France Region","75013","France","FR",{"type":35,"coordinates":36},"Point",[37,38],2.3488,48.85341,{"lat":38,"lon":37},[41,42],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},{"name":19,"role":43,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[47],{"name":48,"class":49},"Boston Scientific Corporation","INDUSTRY","100623319","computed-tomography-of-pulse-field-ablation-100623319",false,"NCT07395089","Computed Tomography of Pulse-Field Ablation","Atrial Remodeling Associated With Pulse-Field Ablation of Atrial Fibrillation: a Computed Tomography Study","CT-PFA","Inclusion Criteria:\n\n1. Age≥18 years at the time of AF ablation\n2. AF ablation by pulse-field ablation (BOSTON SCIENTIFIC FARAPULSE) or by radiofrequency (any manufacturer) between 2020 and 2024\n3. Paroxysmal or non-paroxysmal AF\n4. Pre-ablation CT data available and of high quality\n5. Post-ablation CT data available and of high quality\n6. Post-ablation CT performed 3-months (+- 2 weeks) after AF ablation\n\nExclusion Criteria:\n\n1. Low quality CT, non-homogeneous contrast agent perfusion\n2. Post-ablation CT performed in another center\n3. Patients in which pre- and post-ablation CTs do not share common phases\n4. Patients who underwent ethanol infusion in the vein of Marshall","ALL","18 Years",{"count":61,"type":62},200,"ESTIMATED","OBSERVATIONAL","Radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) reduces left atrial (LA) volume post-ablation, a phenomenon termed reverse atrial remodeling, indicative of successful reversal of atrial cardiomyopathy progression. In contrast, pulse field ablation (PFA), a novel non-thermal technology, offers a promising efficacy and safety profile without inducing persistent atrial fibrosis. While RFCA-associated reverse atrial remodeling is well-documented, it remains uncertain whether PFA, operating on a non-thermal paradigm, also promotes this remodeling, which would enhance its physiological relevance in AF treatment. Additionally, RFCA studies show that LA wall thickness at the pulmonary vein (PV) antrum can predict PV reconnection and arrhythmia recurrence, but whether PFA affects LA thinning or enables similar predictions from post-treatment computed tomography (CT) scans is unknown. Moreover, epicardial adipose tissue (EAT), strongly linked to LA abnormalities and AF recurrence, can be quantified via CT, yet the impact of PFA on LA EAT remains unexplored. Finally, PFA's versatility, particularly in isolating the LA posterior wall (LAPW) in non-paroxysmal AF, raises questions about its effect on posterior wall thinning or EAT changes, factors associated with post-ablation recurrence",[66,67],"Atrial Fibrillation (AF)","Arrhythmia",[69,70,12,71,72,73],"Ablation","Reverse Atrial Remodeling","Pulse Field Ablation","Pulmonary Vein Reconnexion","Epicardial Adipose Tissue","NOT_YET_RECRUITING","2026-02-03",{"date":77,"type":78},"2026-02-09","ACTUAL",{"date":80,"type":62},"2026-02",{"date":80,"type":62},{"name":5,"class":6},1]